| INTRODUCTION
Atrial fibrillation (AF) is a major cause of death and disability and is associated with a 4-to 5-fold increase in the risk of ischemic stroke. 1, 2 With appropriate patient selection, antithrombotic prophylaxis with oral anticoagulation (OAC) therapy reduces the risks of stroke and all-cause mortality by approximately 64% and 26%, respectively. 3 For decades, vitamin K antagonists (VKAs) and antiplatelet drugs were the only treatment choices for stroke prevention in patients with AF. Although VKAs are superior to antiplatelet drugs for stroke prevention, 3, 4 they have many food and drug interactions 5 and require frequent laboratory monitoring. 6 The non-VKA oral anticoagulants (NOACs) were developed to address some of these shortcomings. The direct thrombin inhibitor dabigatran and factor Xa inhibitors apixaban, edoxaban, and rivaroxaban are currently approved for use in the United States and Canada. [7] [8] [9] [10] Compared with warfarin, the NOACs display similar efficacy for stroke prevention and have a generally superior safety profile for bleeding risks, especially for intracranial bleeds. [7] [8] [9] [10] As stroke-prevention therapies have advanced, criteria used to select patients for OAC have also evolved. Current guidelines from the American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS) recommend OAC for patients with a CHA 2 DS 2 -VASc score ≥2. 11 These guidelines also state that in patients with a CHA 2 DS 2 -VASc score of 1, any OAC, aspirin, or no antithrombotic are reasonable. The Canadian Cardiovascular Society (CCS) currently recommends OAC for patients with 1 CHA 2 DS 2 -VASc risk factor other than female sex or vascular disease, and the European Society of Cardiology (ESC) recommends OAC therapy for all males with a CHA 2 DS 2 -VASc score ≥1 and females with a CHA 2 DS 2 -VASc score ≥2. 12, 13 As the global burden of AF has increased, patients are increasing in age, number, and complexity, and there is variability in OAC prescription practice that may, in part, reflect regional practice differences and guidelines. 14, 15 Maximizing the guideline-based use of OAC is an important goal. The recent IMProve treatment with AntiCoagulanTs in patients with Atrial Fibrillation (IMPACT-AF) study demonstrated that educational interventions were able to increase the appropriate use of OAC in patients with AF, and that this was associated with a corresponding reduction in the rate of stroke. 16 Contemporary registries have reported rates of OAC among atrisk patients ranging from 44% to 80%, and regional differences have been observed in global registries. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] Although these registries have Clinical and demographic characteristics, type of AF, and medical therapies were recorded using standard electronic case-report forms.
| METHODS
Clinical data were collected using a validated web-based system. For both descriptive and multivariable regression analyses, missing data points for continuous variables were excluded from the individual analysis in question. Missing data points for categorical variables (eg, medical history) were combined with the "No" category.
| Statistical analysis
The actual numbers of missing data points are listed in the corresponding tables. a The numbers of patients from treatment groups do not add up to the overall column because 27 patients treated with an antiplatelet drug other than ASA or a combination of OACs were not presented.
b For OAC treatment (VKA or NOAC), numbers of patients with missing/unknown values for the following characteristics are: HAS-BLED score (n = 211), CrCl (n = 636), HF (n = 15), HTN (n = 1), prior stroke/TIA (n = 1), prior bleeding (n = 61), alcohol ≥8 U/wk (n = 102), liver disease (n = 16), prior falls (n = 65), cancer (n = 7), COPD/emphysema (n = 12), PAD (n = 12), CAD (n = 28), and prescribers (n = 19). For non-OAC treatment (aspirin or none), numbers of patients with missing/unknown values for the following characteristics are: HAS-BLED score (n = 59), CrCl (n = 157), HF (n = 3), HTN (n = 2), prior stroke/TIA (n = 1), prior bleeding (n = 10), alcohol ≥8 U/wk (n = 32), liver disease (n = 6), prior falls (n = 21), cancer (n = 0), COPD/emphysema (n = 2), PAD (n = 3), CAD (n = 12), and prescribers (n = 7).
| RESULTS
From November 2011 through February 2014, 3320 eligible patients were enrolled from 292 centers. A total of 2934 (88.4%) patients were enrolled from 265 centers in the United States and 386 (11.6%) from 27 centers in Canada. The majority of patients were enrolled from specialist offices (67.6%), followed by primary-care offices (14.6%).
Most prescribing physicians were cardiologists (84.4%). The mean age of the study population was 71 AE 11 years, the mean CHA 2 DS 2 -VASc score was 3.3 AE 1.5, and the mean HAS-BLED score was 1.5 AE 0.9.
Patient demographics and medical history are summarized in Table 1 , grouped according to prescribed therapy.
Use of antithrombotic therapy according to age, stroke risk, and bleeding risk is depicted in Figures 1 and 2 . In patients with a CHA 2 DS 2 -VASc score ≥2, the rate of OAC was significantly lower in those with a HAS-BLED score of ≥3 compared with those with a HAS-BLED score ≤2 (74.0% vs 83.0%, respectively; P < 0.0001). This was accompanied by a significant increase in the proportion of patients managed with aspirin alone (21.7% vs 9.3%, respectively; P < 0.0001).
The results of the multivariable models of factors associated with the choice of OAC prescription as opposed to non-OAC management (antiplatelet drugs or no antithrombotic treatment) are displayed in Table 2 and in Supporting Information, The results of the multivariable prediction models for the selection of NOAC as opposed to VKA therapy in the 2633 patients who received OAC are presented in Table 3 and in Supporting Information, and 81.5% of females and males, respectively. 28 Data from the GARFIELD-AF registry indicate that appropriate OAC has increased over time and this is largely driven by increased use of NOACs. 20 The most recent publication has highlighted factors underpinning the decision between VKA and NOAC. NOACs were chosen more often than VKAs among men, the elderly (age >65 years), patients of Asian ethnicity, those with dementia, those using nonsteroidal antiinflammatory drugs, and current smokers. VKAs were chosen more often than NOACs among patients with cardiac, vascular, and/or renal comorbidities.
Differences in patient characteristics and the rates of medication usage between North American patients and other patients in the global GLORIA-AF registry program have been reported previously. 26 Globally, 80% of patients with a CHA 2 DS 2 -VASc score ≥1 were prescribed OAC and 12% were prescribed therapy with antiplatelet drugs alone. 19, 26 North American patients make up 22.5% of the global cohort and medication usage rates are similar to the overall global trends. Rates of OAC were highest in Europe, where 90% of patients received OAC and 6% were given antiplatelet drugs alone. Slightly higher rates of OAC use in Europe may be driven by the fact that ESC guidelines more strongly suggest OAC for patients with a single CHA 2 DS 2 -VASc risk factor (other than sex) than do guidelines from the United States. 11, 13 In this study, use of antiplatelet drugs, history of falls, prior bleeding, and paroxysmal AF (vs persistent/permanent AF) were identified as potential reasons for not prescribing OAC. In the present cohort, approximately 1 in 4 patients who received OAC also received antiplatelet drugs. The practice of combining antiplatelet drugs and OAC has been associated with increased bleeding without reduction in thrombotic outcomes. 29, 30 Additionally, discontinuing therapy with antiplatelet drugs is one of the modifiable elements of the HAS-BLED score. 31 Outside of specific transient indications such as recent acute coronary syndrome or coronary stent, prescribing concomitant therapy with antiplatelet drugs in patients receiving OAC for AF should be avoided. 12, 13 Falls remain a controversial risk factor for bleeding in patients with AF; [32] [33] [34] however, there is no clear evidence to support falls or a predisposition thereto as a contraindication to OAC. The ESC guidelines recommend withholding therapy only in patients with a predisposition to severe, uncontrolled falls. 13 It is not surprising that patients in this cohort with a history of bleeding were significantly less likely to receive OAC. The approach to stroke prevention in patients with AF and a history of bleeding is challenging. Observational data suggest that in patients who have bled on OAC, resumption of OAC after an appropriate interval impacts positively on stroke and mortality, even after an intracranial bleed. [35] [36] [37] However, many questions remain with respect to the safety, timing, and circumstances under which to initiate or resume OAC after a bleeding event, and randomized studies are required to provide guidance. 13 Bleeding risk also influenced choice of stroke prevention strategy in this cohort. Among patients at higher risk of stroke (ie, CHA 2 DS 2 -VASc score ≥2), those at high risk of bleeding (ie, HAS-BLED score ≥3) were significantly less likely to receive OAC and more likely to receive antiplatelet drugs than those at low risk of bleeding (ie, HAS-BLED score ≤2; Figure 1 ). The superiority of OAC over therapy with antiplatelet drugs for stroke prevention has been well-established in a meta-analysis. 3 The net clinical benefit (balance of stroke and bleeding) of OAC over therapy with antiplatelet drugs has been demonstrated in patients with AF who have additional risk factors for stroke, including those with higher HAS-BLED scores. 38, 39 We advocate that a high HAS-BLED score should not preclude the use of OAC; rather, it should help identify patients who need closer follow-up, addressing reversible factors for bleeding. 13, 40 Patients with paroxysmal AF were less likely to receive OAC than those with persistent or permanent AF. However, the balance of current evidence suggests that although patients with permanent AF appear to have a higher risk of stroke, patients with each of the 3 pat- Most patients (84.4%) had a cardiologist as the prescribing physician and most (67.6%) were seen in a specialist office. This may have affected the number of patients receiving OAC and increased the proportion receiving a NOAC. It is worth noting that these data were collected before the arrival of target-specific reversal agents for NOACs; it remains unknown whether the availability of reversal agents would change decisions to offer OAC and/or to offer a NOAC over VKA.
| CONCLUSION
In this North American cohort of patients with AF, one-fifth of the study population, comprising males with a CHA 2 DS 2 -VASc score ≥1
and females with a CHA 2 DS 2 -VASc score ≥2, did not receive OAC.
CHADS 2 risk factors generally predicted OAC; however, use of antiplatelet drugs, a history of falling, prior bleeding, and paroxysmal AF were identified as potential reasons to not provide OAC.
